Trasylol Clinical Benefit To Be Reviewed By FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Cardiovascular & Renal Drugs Advisory Committee will also consider reports of hypersensitivity and renal and cardiovascular risk linked to Bayer’s aprotinin injection at its Sept. 21 meeting.